Future Directions for the HRS Harmonized Cognitive Assessment Protocol
Author:
Torres Jacqueline M.1ORCID, Glymour M. Maria1
Affiliation:
1. Department of Epidemiology and Biostatistics , UC San Francisco , San Francisco , CA , USA
Abstract
Abstract
In the absence of effective pharmacological treatment to halt or reverse the course of Alzheimer’s disease and related dementias (ADRDs), population-level research on the modifiable determinants of dementia risk and outcomes for those living with ADRD is critical. The Harmonized Cognitive Assessment Protocol (HCAP), fielded in 2016 as part of the U.S. Health and Retirement Study (HRS) and multiple international counterparts, has the potential to play an important role in such efforts. The stated goals of the HCAP are to improve our ability to understand the determinants, prevalence, costs, and consequences of cognitive impairment and dementia in the U.S. and to support cross-national comparisons. The first wave of the HCAP demonstrated the feasibility and value of the more detailed cognitive assessments in the HCAP compared to the brief cognitive assessments in the core HRS interviews. To achieve its full potential, we provide eight recommendations for improving future iterations of the HCAP. Our highest priority recommendation is to increase the representation of historically marginalized racial/ethnic groups disproportionately affected by ADRDs. Additional recommendations relate to the timing of the HCAP assessments; clinical and biomarker validation data, including to improve cross-national comparisons; dropping lower performing items; enhanced documentation; and the addition of measures related to caregiver impact. We believe that the capacity of the HCAP to achieve its stated goals will be greatly enhanced by considering these changes and additions.
Publisher
Walter de Gruyter GmbH
Subject
Health Policy,Economics, Econometrics and Finance (miscellaneous)
Reference41 articles.
1. 2020. “2020 Alzheimer’s Disease Facts and Figures.” Alzheimers Dementia; https://doi.org/10.1002/alz.12068. 2. Ackley, S. F., S. C. Zimmerman, W. D. Brenowitz, E. J. Tchetgen Tchetgen, A. L. Gold, J. M. Manly, E. R. Mayeda, T. J. Filshtein, M. C. Power, F. M. Elahi, A. M. Brickman, and M. M. Glymour. 2021. “Effect of Reductions in Amyloid Levels on Cognitive Change in Randomized Trials: Instrumental Variable Meta-Analysis.” BMJ 372: n156, doi:https://doi.org/10.1136/bmj.n156. 3. Administration for Community Living. 2020. 2019 Profile of Older Americans. Washington, D.C.: U.S. Department of Health and Human Services. Also available at https://acl.gov/sites/default/files/Aging%20and%20Disability%20in%20America/2019ProfileOlderAmericans508.pdf. 4. Brenowitz, W. D., S. C. Zimmerman, T. J. Filshtein, K. Yaffe, S. Walter, T. J. Hoffmann, E. Jorgenson, R. A. Whitmer, and M. M. Glymour. 2021. “Extension of Mendelian Randomization to Identify Earliest Manifestations of Alzheimer Disease: Association of Genetic Risk Score for Alzheimer Disease with Lower Body Mass Index by Age 50 Years.” American Journal of Epidemiology 190 (10): 2163–71, doi:https://doi.org/10.1093/aje/kwab103. 5. Banerjee, J., U. Jain, P. Khobragade, B. Weerman, P. Hu, S. Chien, S. Dey, P. Chaterjee, J. Saxton, B. Keller, E. Crimmins, A. Toga, A. Jain, G. S. Shanthi, R. Kurup, A. Raman, S. Chakrabarti, M. Varghese, J. John, H. Joshi, P. Koul, D. Goswami, A. Talukdar, R. Mohanty, Y. Yadati, M. Padmaja, L. Sankhe, S. Pedgaonkar, P. Arokiasamy, D. Bloom, K. Langa, J. Jovicich, A. Dey, J. Lee, I. Gambhir, and C. Rajguru. 2020. “Methodological Considerations in Designing and Implementing the Harmonized Diagnostic Assessment of Dementia for Longitudinal Aging Study in India (LASI-DAD).” Biodemography and Social Biology 65 (3): 189–213, doi:https://doi.org/10.1080/19485565.2020.1730156.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|